Skip to content
RDL Network logo
Venetoclax Plus Ibrutinib As First-Line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials — Lokman Hekim Tanrıverdi (2024) | RDL Network